Drug Trial Radar · NCT07932808
Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
Nov 26, 2026
Primary completion
Nov 26, 2031
Study completion Nov 26, 2040
Sponsor
- Lead sponsor
- Giselle ShollerAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SERB Pharmaceuticals
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, multicenter, clinical trial in participants with high-risk neuroblastoma that have completed induction therapy, evaluating the feasibility, efficacy, and toxicity of using anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation followed by standard radiation, then standard anti-GD2 immunotherapy, and 2 years of DFMO maintenance.
Conditions
- Neuroblastoma
Interventions
Naxitamab and GM-CSF in combination with irinotecan and temozolomideDrug
anti-GD2 chemo-immunotherapy (naxitamab/irinotecan/temozolomide/GM-CSF) as consolidation
Dinutuximab. ImmunotherapyDrug
Dinutuximab + GM-CSF + Isotretinoin (or Dinutuximab-Beta) for 5 cycles plus Isotretinoin alone in Cycle 6
DFMODrug
DFMO Monotherapy: DFMO for 730 days (2 years)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of days that subjects remain in event freeTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn State Milton S. Hershey Medical Center and Children's Hospital
Hershey, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.